Early MS Treatment Lowers Relapse Rates by 62%

For the millions living with multiple sclerosis, choosing the right treatment has always felt like a shot in the dark. A groundbreaking study just made that choice a lot clearer.

Researchers at Sweden's Karolinska Institutet tracked 509 newly diagnosed MS patients for two years, comparing five different treatment approaches. The results showed that people who started B-cell depleting therapies early had dramatically better outcomes than those who began with standard oral medications.

The numbers tell a powerful story. Patients on B-cell therapies like rituximab and ocrelizumab experienced just 0.04 relapses per year, compared to 0.16 relapses for those taking oral platform treatments. After accounting for age, sex, and how long patients had MS, that translates to 62% fewer relapses.

Brain scans revealed even more good news. People on B-cell therapies showed reduced lesion volume, meaning less disease-related damage to their brains over time. They were also far more likely to stick with their treatment, with 94% still taking their medication after two years.

Dr. Fredrik Piehl, who led the study published in Neurology Open Access in September 2026, emphasized that having more treatment options than ever before has been both a blessing and a challenge. Doctors have struggled to know which therapy to recommend first, especially for younger patients facing decades of disease management.

The study included people with an average age of 33, tracking them from diagnosis through their first two years of treatment. Some received injectable therapies, others took pills, and some started with aggressive high-efficacy treatments or B-cell therapies. About one in five received no treatment initially.

Why This Inspires

This research matters because it gives families facing an MS diagnosis something they desperately need: hope backed by data. For years, choosing an MS treatment meant weighing unknowns against unknowns. Now doctors and patients can have clearer conversations about what to expect.

The findings are especially meaningful because MS typically strikes people in their prime working years. Fewer relapses mean fewer hospitalizations, less time away from work and family, and a better quality of life during crucial decades.

While the study found no differences in disability scores after two years, researchers plan to follow participants longer to see if the benefits grow over time. Even the current results offer a roadmap for the roughly 2.8 million people worldwide living with MS.

Dr. Piehl notes that no single treatment will work best for everyone, and patient characteristics still matter when selecting therapy. But knowing that early aggressive treatment with B-cell therapies is linked to fewer attacks and brain changes gives patients and doctors a stronger foundation for making these life-changing decisions together.